Hanshang Group Past Earnings Performance
Past criteria checks 1/6
Hanshang Group has been growing earnings at an average annual rate of 25.5%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 10.5% per year. Hanshang Group's return on equity is 2.3%, and it has net margins of 3.6%.
Key information
25.5%
Earnings growth rate
20.8%
EPS growth rate
Pharmaceuticals Industry Growth | 10.9% |
Revenue growth rate | 10.5% |
Return on equity | 2.3% |
Net Margin | 3.6% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Hanshang Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 1,365 | 50 | 665 | 42 |
31 Dec 23 | 1,390 | 61 | 675 | 46 |
30 Sep 23 | 1,379 | 94 | 677 | 56 |
30 Jun 23 | 1,387 | 96 | 685 | 56 |
31 Mar 23 | 1,391 | 91 | 682 | 55 |
31 Dec 22 | 1,387 | 90 | 699 | 55 |
30 Sep 22 | 1,389 | 93 | 686 | 55 |
30 Jun 22 | 1,438 | 86 | 707 | 53 |
31 Mar 22 | 1,464 | 87 | 714 | 53 |
31 Dec 21 | 1,475 | 86 | 704 | 49 |
30 Sep 21 | 1,447 | 174 | 702 | 37 |
30 Jun 21 | 1,144 | 133 | 578 | 29 |
31 Mar 21 | 826 | 95 | 449 | 20 |
31 Dec 20 | 495 | 45 | 336 | 14 |
30 Sep 20 | 516 | -68 | 225 | 0 |
30 Jun 20 | 686 | -30 | 239 | 0 |
31 Mar 20 | 899 | 0 | 257 | 0 |
01 Jan 20 | 1,157 | 30 | 279 | 0 |
30 Sep 19 | 1,106 | 36 | 274 | 0 |
30 Jun 19 | 1,096 | 24 | 274 | 0 |
31 Mar 19 | 1,081 | 14 | 269 | 0 |
31 Dec 18 | 1,082 | 20 | 266 | 0 |
30 Sep 18 | 1,079 | 20 | 282 | 0 |
30 Jun 18 | 1,073 | 19 | 279 | 0 |
31 Mar 18 | 1,057 | 17 | 279 | 0 |
31 Dec 17 | 1,012 | 16 | 272 | 0 |
30 Sep 17 | 991 | 12 | 262 | 0 |
30 Jun 17 | 958 | 14 | 253 | 0 |
31 Mar 17 | 940 | 15 | 251 | 0 |
31 Dec 16 | 949 | 12 | 248 | 0 |
30 Sep 16 | 941 | 10 | 232 | 0 |
30 Jun 16 | 962 | 8 | 229 | 0 |
31 Mar 16 | 978 | 8 | 224 | 0 |
31 Dec 15 | 984 | 10 | 218 | 0 |
30 Sep 15 | 982 | 24 | 225 | 0 |
30 Jun 15 | 957 | 22 | 216 | 0 |
31 Mar 15 | 947 | 23 | 214 | 0 |
31 Dec 14 | 941 | 20 | 213 | 0 |
30 Sep 14 | 941 | 17 | 204 | 0 |
30 Jun 14 | 965 | 17 | 204 | 0 |
31 Mar 14 | 1,006 | 15 | 211 | 0 |
31 Dec 13 | 1,003 | 17 | 209 | 0 |
30 Sep 13 | 999 | 23 | 214 | 0 |
30 Jun 13 | 976 | 24 | 208 | 0 |
Quality Earnings: 600774 has a large one-off gain of CN¥23.5M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 600774's current net profit margins (3.6%) are lower than last year (6.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600774's earnings have grown significantly by 25.5% per year over the past 5 years.
Accelerating Growth: 600774's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 600774 had negative earnings growth (-45.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.8%).
Return on Equity
High ROE: 600774's Return on Equity (2.3%) is considered low.